CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 172 enrolled
Drug / intervention
AGN-210669 ophthalmic solution, 0.075% +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00809848
NCT00809848Phase 2Completed
CompareCT.gov

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Allergan·interventional·Posted Dec 17, 2008·Updated Oct 18, 2013

In Brief

A Phase 2 clinical trial evaluating AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, and 3 other interventions for Ocular Hypertension and Glaucoma. Completed, enrolled 172 participants across 1 site.

Detailed Summary

The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or primary open-angle glaucoma. Subjects will be followed for 2 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Glaucoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 17, 2008
Enrollment StartFeb 1, 2009
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.5 years ago

Interventions

AGN-210669 ophthalmic solution, 0.075%drug

AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.

AGN-210669 ophthalmic solution, 0.05%drug

AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.

AGN-210669 ophthalmic solution, 0.025%drug

AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.

bimatoprost ophthalmic solution 0.03%drug

Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.

AGN-210669 vehicle ophthalmic solutiondrug

AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.